Patents by Inventor Kenneth M. Snader
Kenneth M. Snader has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7834005Abstract: Disclosed are compounds of Formula I wherein X, Y, R1-R7, T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula I and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula I; a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula I; a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula I; and a method of preparing a compound of Formula I as described herein.Type: GrantFiled: February 13, 2009Date of Patent: November 16, 2010Assignees: The United States of America as represented by the Department of Health and Human Services, Starks Associates, Inc., Midwest Research Institute, Spirogen, Ltd.Inventors: Paul S. Liu, B. Rao Vishnuvajjala, Kenneth M. Snader, David E. Thurston, Philip W. Howard, Luke Y. Hsiao, Gregory Turner
-
Publication number: 20090149449Abstract: Disclosed are compounds of Formula I wherein X, Y, R1-R7, T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula I and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula I; a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula I; a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula I; and a method of preparing a compound of Formula I as described herein.Type: ApplicationFiled: February 13, 2009Publication date: June 11, 2009Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, Starks Associates, Inc., Midwest Research Institute, Spirogen, Ltd.Inventors: Paul S. Liu, B. Rao Vishnuvajjala, Kenneth M. Snader, David E. Thurston, Philip W. Howard, Luke Y. Hsiao, Gregory Turner
-
Patent number: 7511032Abstract: Disclosed are compounds of Formula (I) wherein X, Y, Ri-R7, T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula (I) and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula (I); a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula (I); a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula (I); and a method of preparing a compound of Formula (I) as described herein.Type: GrantFiled: October 22, 2004Date of Patent: March 31, 2009Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Starks Associates, Inc., Midwest Research Institute, Spirogen, Ltd.Inventors: Paul S Liu, B. Rao Vishnuvajjala, Kenneth M Snader, David E Thurston, Philip W Howard, Luke Y Hsiao, Gregory Turner
-
Patent number: 7244724Abstract: A compound of formula I: or solvate thereof, wherein n is 1 to 10, and M and M? are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.Type: GrantFiled: May 13, 2005Date of Patent: July 17, 2007Assignees: United States of America, Represented by the Secretary, Department of Health and Human Services, Spirogen, Ltd.Inventors: Paul S. Liu, B. Rao Vishnuvajjala, Kenneth M. Snader, David E. Thurston, Philip Howard, Stephen Gregson
-
Patent number: 6890917Abstract: A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.Type: GrantFiled: March 28, 2002Date of Patent: May 10, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kenneth M. Snader, B. Rao Vishnuvajjala, Melinda G. Hollingshead, Edward A. Sausville
-
Patent number: 6812246Abstract: The invention provides an aminoflavone having formula (I), wherein each of R1 and R2 is H, COCH2—R7, wherein R7 is amino alkylamino, dialkylamino, or alkyl- or dialkylaminoalkyl, or an &agr;-amino acid residue, provided that at least one of R1 or R2 is other than H, and R3 is H, branched or straight-chain alkyl, hydroxyalkyl, alkanoyloxyalkyl, alkanoyloxy, alkoxy, or alkoxyalkyl, or pharmaceutically acceptable salts thereof. The present invention also provides a pharmaceutical composition comprising an aminoflavone as described above, and a method of inhibiting the growth of a tumor in a host by administering a tumor growth-inhibiting amount of an aminoflavone compound having the formula as described above.Type: GrantFiled: June 12, 2003Date of Patent: November 2, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kenneth M. Snader, B. Rao Vishnuvajjala, Tsutomu Akama
-
Publication number: 20040053909Abstract: A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administrering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.Type: ApplicationFiled: September 16, 2003Publication date: March 18, 2004Inventors: Kenneth M. Snader, B. Rao Vishnuvajjala, Melinda G. Hollingshead, Edward A. Sausville
-
Publication number: 20040019227Abstract: The invention provides an aminoflavone having formula (I), wherein each of R1 and R2 is H, COCH2—R7, wherein R7 is amino alkylamino, dialkylamino, or alkyl- or dialkylaminoalkyl, or an &agr;-amino acid residue, provided that at least one of R1 or R2 is other than H, and R3 is H, branched or straight-chain alkyl, hydroxyalkyl, alkanoyloxyalkyl, alkanoyloxy, alkoxy, or alkoxyalkyl, or pharmaceutically acceptable salts thereof. The present invention also provides a pharmaceutical composition comprising an aminoflavone as described above, and a method of inhibiting the growth of a tumor in a host by administering a tumor growth-inhibiting amount of an aminoflavone compound having the formula as described above.Type: ApplicationFiled: June 12, 2003Publication date: January 29, 2004Inventors: Kenneth M. Snader, B. Rao Vishnuvajjala, Tsutomu Akama
-
Patent number: 5283383Abstract: The present invention relates to a new antitumor compound, a method for isolating same from a red alga, antitumor compositions containing same and methods of using same for treating patients with cancer. The compound of the present invention is 6(R)-bromo-3(S)-bromomethyl-7-methyl-2,3,7-trichloro-1-octene.Type: GrantFiled: February 18, 1992Date of Patent: February 1, 1994Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Boyd, John H. Cardellina, II, Richard W. Fuller, Kenneth M. Snader, Jon Clardy
-
Patent number: 4942180Abstract: This invention relates to antitumor compositions, and a method for inhibiting, remitting or controlling the growth of tumors or tumor cells utilizing antitumor compositions. More particularly, the antitumor compositions comprise, as active ingredient, an antitumor effective amount of halogenated chamigrenes extracted and derived from red alga and sea hares which diet upon red alga.Type: GrantFiled: September 4, 1985Date of Patent: July 17, 1990Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Tatsuo Higa, Kenneth M. Snader
-
Patent number: 4921873Abstract: This invention relates to antiviral and antitumor compositions, a process for producing the compositions and a method for inhibiting viruses and tumors utilizing the compositions. More particularly, the compositions are cyclohexadienone derivatives which are derived from red alga Desmia hornemanni.Type: GrantFiled: June 14, 1985Date of Patent: May 1, 1990Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Tatsuo Higa, Kenneth M. Snader
-
Patent number: 4902716Abstract: This invention relates to antiviral compositions, a process for producing the compositions and a method for inhibiting viruses utilizing the compositions. More particularly, the compositions are halogenated chamigrenes extracted from sea hares which diet upon red algae.Type: GrantFiled: December 18, 1984Date of Patent: February 20, 1990Assignee: Harbor Branch Oceanographic Institutuion, Inc.Inventors: Tatsuo Higa, Kenneth M. Snader
-
Patent number: 4778846Abstract: A novel process for the isolation and purification of vancomycin class antibiotics which utilized affinity chromatography by the formation of a sorption complex between the antibiotic and an immobilizing ligand selected from -D-alanyl-D-alanine or -X-D-alanyl-D-alanine, wherein X is an amino acid radical and the novel affinity chromatography sorbent employed therein are disclosed.Type: GrantFiled: February 4, 1987Date of Patent: October 18, 1988Assignee: Smithkline Beckman CorporationInventors: Robert D. Sitrin, Kenneth M. Snader, Gail F. Wasserman
-
Patent number: 4708962Abstract: This invention relates to antitumor compositions, and a method for inhibiting, remitting or controlling the growth of tumors or tumor cells utilizing antitumor compositions. More particularly, the antitumor compositions comprise, as active ingredient, an antitumor effective amount of halogenated chamigrenes extracted and derived from red alga and sea hares which diet upon red alga.Type: GrantFiled: September 4, 1985Date of Patent: November 24, 1987Assignee: Harbor Branch Oceanographic Institution, Inc.Inventors: Tatsuo Higa, Kenneth M. Snader
-
Patent number: 4667024Abstract: A novel process for the isolation and purification of vancomycin class antibiotics which utilized affinity chromatography by the formation of a sorption complex between the antibiotic and an immobilizing ligand selected from -D-alanyl-D-alanine or -X-D-alanyl-D-alanine, wherein X is an amino acid radical and the novel affinity chromatography sorbent employed therein are disclosed.Type: GrantFiled: July 13, 1983Date of Patent: May 19, 1987Assignee: SmithKline Beckman CorporationInventors: Robert D. Sitrin, Kenneth M. Snader, Gail F. Wasserman
-
Patent number: 4385122Abstract: A novel anthracycline antibiotic complex, fragilomycin complex, is produced by the cultivation of a fermentation broth containing Streptosporangium fragile Shearer sp. nov. ATCC 31519 microorganisms in an aqueous nutrient medium under submerged aerobic conditions. The fragilomycin complex and its major bioactive component, fragilomycin A, exhibit antibiotic activity.Type: GrantFiled: August 21, 1981Date of Patent: May 24, 1983Assignee: SmithKline Beckman CorporationInventors: Claude H. Nash, III, Marcia C. Shearer, Kenneth M. Snader, Joseph R. Valenta, David Cooper
-
Patent number: 4293546Abstract: A novel anthracycline antibiotic complex, fragilomycin complex, is produced by the cultivation of a fermentation broth containing Streptosporangium fragilis Shearer sp. nov. ATCC 31519 microorganisms in an aqueous nutrient medium under submerged aerobic conditions. The fragilomycin complex and its major bioactive component, fragilomycin A, exhibit antibiotic activity.Type: GrantFiled: July 24, 1980Date of Patent: October 6, 1981Assignee: SmithKline CorporationInventors: Claude H. Nash, III, Marcia C. Shearer, Kenneth M. Snader, Joseph R. Valenta, David Cooper
-
Patent number: 4292305Abstract: Imidodisulfamide derivatives useful in the treatment of allergic conditions are prepared by reaction of an appropriately substituted primary amine and bis(chlorosulfonyl) imide in the presence of a tertiary amine.Type: GrantFiled: February 13, 1980Date of Patent: September 29, 1981Assignee: SmithKline CorporationInventors: Fadia E. Ali, Robert D. Krell, Kenneth M. Snader
-
Patent number: 4165365Abstract: Substituted 2H-pyran-2,6(3H)-dione derivatives useful in the treatment of allergic conditions are prepared by reaction of 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one with an appropriate aniline.Type: GrantFiled: March 10, 1978Date of Patent: August 21, 1979Assignee: SmithKline CorporationInventor: Kenneth M. Snader
-
Patent number: 4160021Abstract: Substituted 2H-pyran-2,6(3H)-dione derivatives useful in the treatment of allergic conditions are prepared by reaction of 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one with an appropriate aniline.Type: GrantFiled: March 10, 1978Date of Patent: July 3, 1979Assignee: SmithKline CorporationInventor: Kenneth M. Snader